Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Investment analysts at Leerink Partnrs issued their FY2025 EPS estimates for shares of Xeris Biopharma in a research note issued on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings per share of ($0.05) for the year. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma's FY2026 earnings at $0.10 EPS and FY2027 earnings at $0.30 EPS.

Several other analysts have also weighed in on XERS. Wall Street Zen lowered shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Craig Hallum boosted their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research report on Friday, March 7th. Leerink Partners increased their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research note on Friday, March 7th. HC Wainwright restated a "buy" rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, Xeris Biopharma has a consensus rating of "Moderate Buy" and a consensus target price of $6.25.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS traded up $0.04 during trading on Monday, reaching $4.42. The stock had a trading volume of 1,117,095 shares, compared to its average volume of 1,975,153. The firm's 50 day moving average price is $4.54 and its two-hundred day moving average price is $4.10. Xeris Biopharma has a one year low of $2.03 and a one year high of $6.07. The stock has a market cap of $691.22 million, a PE ratio of -9.82 and a beta of 0.71.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of XERS. Legato Capital Management LLC acquired a new stake in Xeris Biopharma in the 4th quarter valued at about $482,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Xeris Biopharma by 106.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company's stock valued at $581,000 after purchasing an additional 88,224 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Xeris Biopharma by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock worth $26,778,000 after buying an additional 133,738 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Xeris Biopharma by 10.5% during the fourth quarter. Principal Financial Group Inc. now owns 113,217 shares of the company's stock worth $384,000 after buying an additional 10,748 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Xeris Biopharma in the fourth quarter worth approximately $45,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Beth Hecht sold 40,000 shares of the business's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. The trade was a 2.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.47% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.